AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00566917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior colporrhaphy
Description: Standardised colporrhaphy of the anterior vaginal wall
Study NCT00566917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior PROLIFT
Description: Transvaginal mesh surgery of the anterior vaginal wall
Study NCT04495855 — intervention group
Intervention type: DRUG
Intervention: Dienogest (Visanne,BAY86_5258)
Description: 2 mg (once a day), oral, tablet.
Study NCT03045783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotiam
Description: Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
Study NCT02365753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofPulse
Description: Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
Study NCT02365753 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SofPulse
Description: Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
Study NCT01177384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
Study NCT01177384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
Study NCT01177384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acarbose
Description: Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
Study NCT01177384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
Study NCT01177384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
Study NCT01177384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
Study NCT02649296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skanlab bodywave
Description: The intervention will be done twice a week
Study NCT03595319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhaled sevoflurane until allocated dose (see adaptive protocol)
Study NCT02361827 — intervention group
Intervention type: PROCEDURE
Intervention: Embryo transfer
Description: For patients in each group after oocyte retrieval, they will have embryo transferred 3 or 5 days after oocyte retrieval. For FET cycles, they will have ET with an euploid blastocyst.
Study NCT00909233 — intervention group
Intervention type: DRUG
Intervention: Vardenafil, (Levitra, BAY38-9456)
Description: Patients under daily life treatment receiving Levitra according to local drug information.
Study NCT03429439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intestinal microbiota transplant
Description: Participants in experimental group take 6 times IMT with 2-week intervals.
Study NCT03429439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antiviral Agents
Description: All participants continue present antiviral therapy over 12 months.
Study NCT03429439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral Agents
Description: All participants continue present antiviral therapy over 12 months.
Study NCT03708120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrepel (Insect Repellent) EPA Reg. No. 84878-2
Description: Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
Study NCT00606450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: 20 mg CC-10004 taken 1 time per day for 12 weeks
Study NCT00606450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: 20 mg of CC-10004 taken 2 times per day for 12 weeks
Study NCT00606450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo taken either 1 or 2 times per day for 12 weeks
Study NCT04593667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hm-P bandage
Description: hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
Study NCT03084406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centervention-ATOD (CV-ATOD)
Description: A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
Study NCT00127920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
Study NCT00809419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoVista Ophthalmic System
Description: A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
Study NCT02368067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Sentinal Node Dye
Description: Delivery of sentinal node dye by different routes
Study NCT02368067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Sentinal Node Dye
Description: Patients will receive different types of dye by different routes of administration
Study NCT03327441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Almonds will be provided as 15% energy
Study NCT03327441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omelette
Description: Omelettes will be provided as 15% energy
Study NCT00472173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: Apexification treatment of the tooth with Mineral Trioxide Aggregate
Study NCT00472173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Apexification treatment of the tooth with Calcium hydroxide
Study NCT02247154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigam® (Human Normal Immunoglobulin)
Study NCT04195035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q intubating laryngeal airway
Description: Air-Q intubating laryngeal airway will be used for ventilation \& intubation through fiberoptic bronchoscope.
Study NCT04195035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu-Aura intubating laryngeal mask
Description: Ambu-Aura intubating laryngeal mask will be used for ventilation \& intubation through fiberoptic bronchscope.
Study NCT02753660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional sitting position
Description: Subjects were set on traditional sitting position before spinal anesthesia begun.
Study NCT02753660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pendant position
Description: Subjects were set on pendant position before spinal anesthesia begun.
Study NCT00601705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
Study NCT00601705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: 50 mg/m2 IV bolus
Study NCT00601705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
Study NCT00601705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130 mg/m2 IV infusion over 2 hours
Study NCT00601705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
Study NCT00601705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible.
Study NCT00627783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a bicycle exercise test
Study NCT03764371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: KAPA Hyper Prep Kit + Agilent SureSelectQXT
Description: We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
Study NCT02790138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab Placebo
Description: Vedolizumab placebo-matching IV infusion
Study NCT02790138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin tablets
Study NCT02790138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion
Study NCT03723317 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: First deceased-donor liver transplantation
Study NCT01321359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle versus NB-001
Description: Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
Study NCT01321359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle versus NB-001
Description: Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
Study NCT03422679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
Study NCT01147198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to Use Supplementary Food
Description: Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
Study NCT01147198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Premix CSB-oil treatment
Description: Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
Study NCT04588194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
Study NCT04588194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 100 mg weekly days 1, 7, 14, 21
Study NCT04588194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg IV/PO days 1-4
Study NCT03391206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inbody 720
Description: We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
Study NCT03838055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of tracer ( ICG) and detection of sentinel lymph nodes
Description: Pelvic SLN's defined by ICG injected cervically
Study NCT02098720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Study NCT06059924 — intervention group
Intervention type: OTHER
Intervention: Anastomotic leakage
Description: Anastomotic leakage was defined as a defect of the intestinal wall at the anastomotic site leading to a communication between the intra- and extraluminal compartments. It was diagnosed by clinical, laboratory, radiological (ultrasound, endosonography, computed tomography), endoscopic, and/or surgical findings.
Study NCT03306355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material
Study NCT03306355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator
Description: Implantation of trifocal IOL POD F consisting of hydrophilic material
Study NCT06478355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.
Study NCT06478355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W
Study NCT06478355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
Study NCT04278300 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
Study NCT04278300 — intervention group
Intervention type: BIOLOGICAL
Intervention: faecal sampling (optional)
Description: analysis of the microbiota by DNA sequencing
Study NCT01766271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: biweekly health coaching for 5 months
Study NCT01766271 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 9p21
Description: Genetic testing results of 9p21
Study NCT01766271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Risk Assessment
Description: All 4 arms are assigned to receive standard assessment on coronary heart disease risk
Study NCT02674698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Access to the CNH Dashboard Step 1
Description: VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
Study NCT02674698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Access to the CNH Dashboard Step 2
Description: VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
Study NCT02674698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Access to the CNH Dashboard Step 3
Description: VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
Study NCT02674698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Access to the CNH Dashboard Step 4
Description: VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
Study NCT00515736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E
Description: Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
Study NCT00515736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle
Study NCT03453658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual instrumentation
Description: Manual conventional files will be used in endodontic treatment of primary teeth
Study NCT03453658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciprocating Instrumentation
Description: Reciprocating files system will be used in endodontic treatment of primary teeth.
Study NCT00955279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
Study NCT00955279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
Study NCT00955279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
Study NCT01114282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velcade
Study NCT01114282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Study NCT05016206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan tablets administered as a single oral dose.
Study NCT05016206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin-matching Placebo
Description: Moxifloxacin-matching placebo was administered as a single oral dose.
Study NCT05016206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching Placebo
Description: Moxifloxacin-matching placebo was administered as a single oral dose.
Study NCT05016206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danicopan-matching placebo
Description: Danicopan-matching placebo was administered as a single oral dose.
Study NCT05016206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg was administered as a single tablet oral dose.
Study NCT00236925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose Hydrocortisone
Description: Hydrocortisone 10 mg daily
Study NCT00236925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Hydrocortisone
Description: Hydrocortisone 10 mg daily
Study NCT00236925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00236925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01560923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Given twice daily (1200 mg total) by mouth for 6 months.
Study NCT01560923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
Study NCT01560923 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sipuleucel-T
Description: Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
Study NCT01560923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given in same manner as Indoximod; 1200 mg per day by mouth.
Study NCT02542384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 IV 1 mcg/kg
Description: CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.